Samya Shafi, MD
Infectious Disease · Butler, NJNPI 1992813398
Payments from drug & device makers
Across 207 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Shionogi Inc$476
- Merck$435
- Insmed, Inc.$400
- Gilead$397
- Viiv Healthcare Company$341
- plus $996 from 14 others
What the payments were for
- Food & beverage$3,94796%
- Education$1644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $1,066 |
| Shionogi Inc | 23 | $476 |
| Merck | 24 | $435 |
| Insmed, Inc. | 22 | $400 |
| Gilead | 18 | $397 |
| Viiv Healthcare Company | 16 | $341 |
| Paratek Pharmaceuticals, Inc. | 12 | $219 |
| Johnson & Johnson(2 entities) | 10 | $201 |
| Astellas Pharma US Inc | 4 | $167 |
| La Jolla Pharmaceutical Company | 4 | $99 |
| Melinta Therapeutics, LLC | 4 | $88 |
| Abbott | 2 | $40 |
| Amgen | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Sandoz | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$4,111 in reported general payments places this provider in the 75th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 76 | $82,231 |
| ErtapenemErtapenem Sodium | 52 | $25,949 |
| CeftriaxoneCeftriaxone Sodium | 58 | $7,601 |
| Cefepime Hcl | 37 | $7,413 |
| MicafunginMicafungin Sodium | 12 | $7,130 |
| Meropenem | 36 | $5,739 |
| Vancomycin Hcl | 33 | $5,701 |
| Methenamine Hippurate | 59 | $4,684 |
| Penicillin G Potassium | 15 | $4,068 |
| Fosfomycin Tromethamine | 28 | $1,994 |
| Cefpodoxime Proxetil | 26 | $1,627 |
| Linezolid | 33 | $1,446 |
| Cefdinir | 72 | $1,006 |
| Doxycycline Hyclate | 85 | $914 |
| Ketoconazole | 27 | $828 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Butler
- Jihad SlimNewark$6.7M
- Ronald NahassHillsborough$6.1M
- Bindu BalaniHackensack$4.9M
- Suraj SaggarEnglewood$2.9M
- Christopher LucastiSomers Point$2.8M
- Edward LiuNeptune$2.6M
- Keith GottesdienerRahway$2.1M
- Amna YaqubFlemington$1.4M
- Shobha SwaminathanNewark$1.4M
- Mohamed RabbatPaterson$760K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.